Page last updated: 2024-09-02

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and n-methylaspartate

alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol has been researched along with n-methylaspartate in 4 studies

Compound Research Comparison

Studies
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)
Trials
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)
Recent Studies (post-2010)
(alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol)
Studies
(n-methylaspartate)
Trials
(n-methylaspartate)
Recent Studies (post-2010) (n-methylaspartate)
901210,408591,902

Protein Interaction Comparison

ProteinTaxonomyalpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (IC50)n-methylaspartate (IC50)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)5.175
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)5.175
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)5.175
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)5.175
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)5.175
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)5.175
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)5.175

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Montigny, C; Debonnel, G; Fournier, A; Monnet, FP1
Borosky, SA; Clissold, DB; Ferkany, JW; Goode, S; Karbon, EW; Patch, RJ; Pontecorvo, MJ1
Bergeron, R; De Montigny, C; Debonnel, G1
Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB1

Other Studies

4 other study(ies) available for alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol and n-methylaspartate

ArticleYear
Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 263, Issue:3

    Topics: Animals; Cinnamates; Cyclopropanes; Drug Synergism; Guanidines; Haloperidol; Hippocampus; Male; N-Methylaspartate; Neuropeptide Y; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Neuropeptide Y; Receptors, sigma; Spiperone

1992
Possible cerebroprotective and in vivo NMDA antagonist activities of sigma agents.
    Brain research bulletin, 1991, Volume: 26, Issue:3

    Topics: Animals; Anticonvulsants; Brain Diseases; Electroshock; Haloperidol; Hypoxia; Male; Mice; Mice, Inbred Strains; N-Methylaspartate; Nimodipine; Piperidines; Postural Balance; Pyrimidines; Receptors, Opioid; Receptors, sigma; Seizures

1991
Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands.
    European journal of pharmacology, 1993, Aug-24, Volume: 240, Issue:2-3

    Topics: 1-Naphthylamine; Animals; Antidepressive Agents; Clorgyline; Electrophysiology; Haloperidol; Male; N-Methylaspartate; Paroxetine; Pyramidal Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sertraline; Tranylcypromine

1993
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
    Neuroreport, 2008, Jan-08, Volume: 19, Issue:1

    Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors

2008